In addition, in lung cancer cells, PD-L1 inhibition combined with Ox/Cy (Oxaliplatin/cyclophosphamide) has been reported to improve the anti-cancer effects of CAR-T cells by increasing the amount of PD-1+ CAR-T cells, and the expression level of PD-L1 on tumor macrophages [99]. This evidence concerns the gene CD274 and lung carcinoma.